Transmission of COVID-19 Virus Among Patients and Staff in Dialysis Centers (DIAL-COVID-19)

February 16, 2023 updated by: Simeone Andrulli, MD

Transmission of COVID-19 Among Patients and Health Personnel in Dialysis Centers: a Cohort Prospective Study (DIAL-COVID-19)

Patients on dialysis are at risk for several infectious diseases, since they have reduced immunological and have to regularly attend dialysis centres even if a pandemic is going on. Dialysis patients and healthcare professionals of dialysis centres can become infected one with the other. The incident risk of COVID-19 in dialysis centres is still unknown.

Given the challenges of an early diagnosis of COVID-19, the likely transmission with outbreaks, the possibility of reciprocal transmission of the infection among patients and healthcare professionals, the frequent clinical severity of COVID-19 in dialysis patients because of the coexistence of several comorbidities, CONTACT TRACING could be an effective and efficient tool to contrast COVID-19 spreading in dialysis centres.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Patients on dialysis are at risk for several infectious diseases, since they have reduced immunological and have to regularly attend dialysis centres from once to thrice a week depending on their residual renal function even if a pandemic is going on.

Dialysis patients and healthcare professionals of dialysis centres can become infected one with the other.

The incident risk of COVID-19 in dialysis centres is still unknown. Given the challenges of an early diagnosis of COVID-19, the likely transmission with outbreaks, the possibility of reciprocal transmission of the infection among patients and healthcare professionals, the frequent clinical severity of COVID-19 in dialysis patients because of the coexistence of several comorbidities, CONTACT TRACING could be an effective and efficient tool to contrast COVID-19 spreading in dialysis centres. This modality keeps trace of the contacts the new COVID-19 case have had and allow the identification of other possible cases in that outbreak

Contact tracing is the key tool to detect and trace COVID-19 cases among patients and health care professionals, i.e. the space-time mapping of the contacts among these two categories:

  1. Daily for healthcare professionals
  2. At every dialysis session for haemodialysis patients
  3. At every hospital visit for patients on peritoneal dialysis

Maximum follow will be up to 12 months excepting in those patients who develop a COVID-19-related clinically significant event:

  1. Diagnosis of symptomatic COVID-19 with or without hospitalisation
  2. Respiratory insufficiency with the need of CPAP or mechanical ventilation
  3. Death associated or related to COVID-19

In the participating centres, the enrolment of patients and healthcare professionals will be prospective, progressive and competitive till the number of cases of COVD-19 will reach 200 subjects. If study participation will be 10% and COVID-19 will be taken by 4% of the patients with no prior exposure to COVID-19, we can estimate to enrol 5000 subjects (dialysis patients and healthcare professionals) over a period of 12 months in 50-150 centres. The length of the enrolment period of 6-12 months will depend also on future evolution of the pandemic in the Italian regions that have not been massively hit by the infection.

Study data will be stored on a web-database, which will be created on purpose. Privacy protection of patients and health care professionals will be pursued and granted by anonymous data collection.

Given the longitudinal and prospective design of the study, Kaplan-Meier curves will be used to describe the incidence of COVID-19 infection and the survival of dialysis patients and their healthcare professionals.

Cox multivariate analysis will be used to:

  1. Estimate the incidence, morbidity and mortality of COVID-19 in the two categories
  2. Estimate predictors and/or confounders associated with the incidence of the three study outcomes (infection, morbidity and mortality)

Study Type

Observational

Enrollment (Actual)

2847

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Catania, Italy
        • Cannizzaro
      • Catanzaro, Italy
        • AOU Mater Domini
      • Firenze, Italy
        • AOU Careggi
      • Foggia, Italy
        • Policlinico
      • Mazara Del Vallo, Italy
        • CEM-Mazara
      • Nuoro, Italy
        • Osp. San Francesco
      • Pescia, Italy
        • SOS Nefrologia di Pescia
      • Prato, Italy
        • Ospedale di Santo Stefano
      • Roma, Italy
        • Ambulatorio Dialisi di Tivoli
      • Roma, Italy
        • Geramed Srl

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

  1. Patients on haemodialysis
  2. Patients on peritoneal dialysis
  3. Healthcare professionals in charge of dialysis patients

Description

Inclusion Criteria:

  1. All the patients on haemodialysis or peritoneal dialysis giving their consent to participate
  2. All healthcare professionals in charge of dialysis patients giving their consent to participate

Exclusion Criteria:

  1. Dialysis patients or healthcare professionals who already have had Covid-19
  2. Patients with kidney transplant
  3. Patients with acute kidney injury (AKI) or on dialysis for less than 3 months
  4. Life expectancy lower than 6 months
  5. Patients already enrolled in other clinical trials
  6. Absence of the consent to participate

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Hemodialysis or peritoneal dialysis patients
Hemodialysis or peritoneal dialysis Covid negative patients
Prospective observation until one year follow-up
dialysis staff healthcare professionals
dialysis staff Covid negative healthcare professionals
Prospective observation until one year follow-up

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
incident risk of COVID-19 infection
Time Frame: 1 year
incident risk of COVID-19 infection in dialysis patients and in related dialysis healthcare professionals
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluate the morbidity of COVID-19
Time Frame: 1 year
Evaluate the morbidity (hospitalisation rate) of COVID-19 in the two subject categories
1 year
Evaluate the mortality of COVID-19
Time Frame: 1 year
Evaluate the mortality rate of COVID-19 in the two subject categories
1 year
Estimate the predictive role of comorbidities, inflammation indexes and therapy on the hospitalisation rate
Time Frame: Three months
Estimate the predictive role of comorbidities, inflammation indexes and therapy on the hospitalisation rate in the three months after COVID-19 diagnosis
Three months
Estimate the predictive role of comorbidities, inflammation indexes and therapy on the mortality rate
Time Frame: Three months
Estimate the predictive role of comorbidities, inflammation indexes and therapy on the mortality rate in the three months after COVID-19 diagnosis
Three months
Evaluate the infective role of dialysis staff towards patients
Time Frame: 1 year
Evaluate the infective role of dialysis staff towards patients over one year follow-up
1 year
Evaluate the infective role of patients towards dialysis staff
Time Frame: 1 year
Evaluate the infective role of patients towards dialysis staff over one year follow-up
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2020

Primary Completion (Actual)

March 31, 2022

Study Completion (Actual)

March 31, 2022

Study Registration Dates

First Submitted

September 23, 2020

First Submitted That Met QC Criteria

September 24, 2020

First Posted (Actual)

September 25, 2020

Study Record Updates

Last Update Posted (Estimate)

February 20, 2023

Last Update Submitted That Met QC Criteria

February 16, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Covid19

Clinical Trials on Prospective observation

3
Subscribe